# EDGAR Filing Document

**Accession Number:** 0001726711
**File Stem:** 0001213900-26-035644
**Filing Date:** 2026-3
**Character Count:** 5059
**Document Hash:** cd42eaeb85597590e29c5a1fce4d3319
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-035644.hdr.sgml**: 20260327

**ACCESSION NUMBER**: 0001213900-26-035644

**CONFORMED SUBMISSION TYPE**: 424B5

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260327

**DATE AS OF CHANGE**: 20260327

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Aditxt, Inc.
- **CENTRAL INDEX KEY:** 0001726711
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 823204328
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 424B5
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-280757
- **FILM NUMBER:** 26808372

**BUSINESS ADDRESS:**
- **STREET 1:** 737 N. FIFTH STREET, SUITE 200
- **CITY:** RICHMOND
- **STATE:** VA
- **ZIP:** 23219
- **BUSINESS PHONE:** 909-488-0844

**MAIL ADDRESS:**
- **STREET 1:** 737 N. FIFTH STREET, SUITE 200
- **CITY:** RICHMOND
- **STATE:** VA
- **ZIP:** 23219

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Aditx Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20201113

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ADiTx Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20171229

**Filed pursuant to Rule 424(b)(5)**

**Registration No. 333-280757**

**SUPPLEMENT NO. 3 TO**

**PROSPECTUS SUPPLEMENT DATED OCTOBER 25, 2024**

**(To Prospectus dated August 6, 2024)**

![](ea028383101_img1.jpg)

**Up to $53,398,964**

**Common Stock**

This prospectus supplement amends and supplements the prospectus dated August 6, 2024, filed as a part of our registration statement on Form S-3 (File No. 333-280757) as amended by our prospectus supplements dated October 25, 2024, April 3, 2025, and December 12, 2025 (the "Prior Prospectuses"). This prospectus supplement should be read in conjunction with the Prior Prospectuses, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the Prior Prospectuses. This prospectus supplement is not complete without, and may only be delivered or utilized in connection with, the Prior Prospectuses, and any future amendments or supplements thereto.

We filed the Prior Prospectuses to register the offer and sale of our common stock, par value $0.001 per share, from time to time pursuant to the terms of that certain At The Market Offering Agreement, or the sales agreement, between H.C. Wainwright & Co., LLC, or Wainwright, acting as the agent, and us (the "ATM Offering").

We are filing this prospectus supplement to amend the Prior Prospectuses to increase the maximum aggregate gross sales price of our common stock that may be offered, issued and sold under the sales agreement from and after the date hereof by an additional $36,800,000 or up to $53,398,964 (the "ATM Offering Size Increase"), not including the shares of common stock previously sold. Under the prospectus supplement dated October 25, 2024, we initially registered up to $35,000,000 of our common stock for offer and sale pursuant to the sales agreement, which was reduced to $11,840,454 pursuant to the prospectus supplement dated April 3, 2025, and increased to $20,000,000 pursuant to the prospectus supplement dated December 12, 2025. As of the date of the filing of this prospectus supplement, we have sold approximately 398,950 shares of our common stock covered by the Prior Prospectuses pursuant to the sales agreement for aggregate gross sales proceeds of approximately $21,257,000, leaving approximately $16,500,000 remaining under the Prior Prospectuses. This prospectus supplement authorizes an additional $36,800,000 of common stock for offer and sale or up to $53,398,964 in the aggregate, representing the remaining available capacity under our registration statement to which this supplement forms a part.

The purpose of this prospectus supplement is to update the Prior Prospectuses to reflect the ATM Offering Size Increase. Except as modified by this prospectus supplement, the terms of the ATM Offering remain unchanged, and the sales agreement remains in full force and effect.

Our prior prospectus supplement dated April 3, 2025 indicated that we were, at that time, subject to General Instruction I.B.6. of Form S-3, which limited the amount that we were able to sell under the registration statement of which the prospectus forms a part. We are currently no longer subject to the offering limits imposed by General Instruction I.B.6. of Form S-3.

Our common stock is traded on The Nasdaq Capital Market under the symbol "ADTX." On March 27, 2026, the last reported sale price of our common stock as reported on the Nasdaq Capital Market was $0.81 per share.

**Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.**

**H.C. Wainwright & Co.**

The date of this prospectus supplement is March 27, 2026.